2 active not recruiting, 2 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 2 |
Follow Metastatic Bladder Carcinoma: new trials by email Literature Review of Metastatic Bladder Carcinoma trials Research Report on Metastatic Bladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2020-11-03 | 2026-11-12 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-11-12 |
Urinary Bladder Neoplasms (4) · Urachal adenocarcinoma (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Urogenital Neoplasms (3) · Neoplasms by Histologic Type (2) · Ureteral Diseases (2) · Urethral Diseases (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · cabozantinib (1) · enfortumab vedotin (1) · olaparib (1) · pembrolizumab (1) · tocilizumab (1)
National Cancer Institute (NCI) (2) · Emory University (1) · M.D. Anderson Cancer Center (1)
United States (4) · Puerto Rico (1)
Andrea B Apolo (2) · Jacqueline Brown, MD (1) · Rodabe Amaria, MD (1)
PMID 35031545, PMID 35537412, PMID 37328287
P30CA138292 (1), U10CA180821 (1), ZIABC011078 (1)